Combined use of biomarkers for detection of ovarian cancer in high-risk women

Tumor Biology

Volumn 31, Issue 3, 2010, Pages 209-215

  Donach, Martin ^a   Yu, Yinhua ^b,d   Artioli, Grazia ^a   Banna, Giuseppe ^a   Feng, Weiwei ^b,d   Bast, Robert C ^b   Zhang, Zhen ^c   Nicoletto, Maria O ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Artificial neural network; Biomarker; High risk; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 125 II ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; PROTEIN OVX1; TUMOR MARKER; UNCLASSIFIED DRUG; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 72 4 ANTIGEN; CA-72-4 ANTIGEN; GLYCOPROTEIN; MUCIN 1; OVX1 ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; BENIGN TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY METASTASIS; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BLOOD; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PELVIC INFLAMMATORY DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BRCA1 PROTEIN; BRCA2 PROTEIN; CA-125 ANTIGEN; CA-19-9 ANTIGEN; FEMALE; GLYCOPROTEINS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953250237     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0032-x     Document Type: Article

References (22)

1. Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-7.
2. Zanaboni F, Vergadoro F, Presti M, Gallotti P, Lombardi F, Bolis G. Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma. Gynecol Oncol. 1987;28:61-7.
3. Zurawski Jr VR, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988;42:677-80.
4. Zurawski Jr VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30:7-14.
5. Malkasian Jr GD, Knapp RC, Lavin PT, Zurawski Jr VR, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988;159:341-6.
6. Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol. 1988;159:873-6.
7. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol. 1988;71:751-6.
8. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol. 1992;44:147-54.
9. Cannistra SA. Cancer of the ovary. N Engl JMed. 2004;351:2519-29.
10. Bast Jr RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;3:274-81.
11. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol. 1999;73:56-61.
12. Lawicki S, Szmitkowski M, Wojtukiewicz M. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta. 2006;371:112-6.
13. Trecate G, Vergnaghi D, Manoukian S, Bergonzi S, Scaperrotta G, Marchesini M, et al. MRI in the early detection of breast cancer in women with high genetic risk. Tumori. 2006;92:517-23.
14. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2006;100:20-6.
15. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993;85:1748-51.
16. Xu FJ, Yu YH, Li BY, Moradi M, Elg S, Lane C, et al. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res. 1991;51:4012-9.
17. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke- Pearson D, et al. Increased serum levels of macrophage colonystimulating factor in ovarian cancer. Am J Obstet Gynecol. 1991;165:1356-62.
18. Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004;22:4059-66.
19. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007;107:526-31.
20. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19:675-81.
21. Joyner AB, Runowicz CD. Ovarian cancer screening and early detection. Womens Health (Lond Engl). 2009;5:693-9. Review.
22. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, et al. OVX1, macrophage-colony stimulating factor, and CA- 125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001;92:2837-44.